Treatment AI Passes Medical School Clinical Exam with 92% Success Rate

VANCOUVER, British Columbia, March 20, 2024 – AI Inc. (OTCQB: TREIF) (CSE: TRUE) (Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam […]

3 Marijuana Stocks That Have Made Recent Headlines

USA NEWS GROUP MARKET COMMENTARY   Vancouver, BC – April 16, 2021 – USA News Group  –  The marijuana industry is a budding sector that is increasing rapidly as more companies become public in the U.S. and Canada, but some of them are overvalued and can be attractive to short sellers. While investors are drawn […]

Recent Earning Reports for Mobile Gaming Stocks Showing Healthy, Steady Growth

Palm Beach, FL – August 10, 2020 – The global health pandemic has had an incredibly negative impact on most businesses and markets across the globe, but there are actually some markets that have thriving because of the pandemic. The global gaming market is one of those exceptions. Revenues are booming in this industry this […]

QMC Irgon Lithium Mine Project Update

Vancouver, BC – April 21, 2020 – QMC Quantum Minerals Corp., (TSXV: QMC) (FSE: 3LQ) (OTC Pink: QMCQF) (“QMC” or “the Company”) is pleased to provide a corporate update. The Company has had recent discussions with Sinomine Group Co., Ltd. (“Sinomine”) to process spodumene material from the Irgon Lithium Mine Property at the TANCO plant. The […]

Hoth Therapeutics Commences Next Phase of VNLG-152 Study

Solubility and formulation had been established for the drug in the treatment of dermatological diseases   New York, NY- April 09, 2020 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152, a Novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, […]

Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue

Pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery and replication in tumor tissue   San Diego, CA – December 3, 2019 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that Matt Coffey, President & CEO of Oncolytics Biotech, will be presenting […]

Soliton Completes Trial Enrollment and Conducts Initial Site Training to Start Keloid Trial

Houston, TX – September 17, 2019 – Soliton, Inc., (NASDAQ: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has completed its site initiation visit for the […]